Alpha Tau Medical
Shoshana Javitt's work experience includes a role as a QA Engineer at Alpha Tau Medical starting in 2021. Prior to that, they worked at InfinityLabs R&D from 2018 to 2020 as a Technical Writer and Curriculum Developer, where they revised and edited curriculum for a software boot camp, prepared a business proposal, and translated marketing material. From 2017 to 2017, Shoshana was a Product Engineering Intern in the Operations Leadership and Development Program at Siemens Healthineers, where they supported product transition to manufacturing and resolved technical and logistical issues. In 2016, they worked as a Process Engineering Intern in the Operations Leadership and Development Program at Siemens Healthineers, where they led a project to improve Incoming Quality Control from suppliers. Prior to that, Shoshana was a Laboratory Intern at Princeton University in 2015, conducting research on encapsulation of nanoparticles for photoacoustic imaging. Shoshana also worked as a Laboratory Intern at Bar-Ilan University in 2014, researching exfoliation methods for nanomaterials. Their earliest work experience was as an Administrative Assistant and Lab Technician at Bruriah High School from 2012 to 2013.
Shoshana Javitt attended Bruriah High School, where they completed their high school education. After graduating from high school, they enrolled at the University of Maryland - A. James Clark School of Engineering in 2014. There, they obtained a Bachelor of Science (BS) degree in Materials Science Engineering, which they completed in 2018. Following their undergraduate studies, Shoshana pursued further education in the field of Software Development at InfinityLabs R&D from 2018 to 2019. Before attending university, they spent a year studying at Yeshiva University in 2013.
Alpha Tau Medical
Alpha Tau Medical (https://www.alphatau.com/) focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid cancer tumors. Initially developed at Tel Aviv University, Alpha DaRT was shown to be effective and safe for treating different types of cancer in multiple animal studies. The company is running its first clinical trial in several sites in the EU and is currently commencing clinical trials at over 55 leading cancer centers worldwide.